← All trials
NCT05395624
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- May 31, 2023
- First posted
- May 27, 2022
- Last posted
- May 27, 2022
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ashvattha Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.